Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylonitrile SCHEMBL571857 | 0.98 | ALDH1A1 (0.38) | ALDH1A1TSHRCYP1A2 | |
| Acrylic Acid Methyl Ester SCHEMBL10882458 | 0.84 | CYP1A2 (0.30) | CYP1A2 | |
| SCHEMBL127251 | 0.82 | — | — | |
| SCHEMBL8206350 | 0.81 | TDP1 (0.50) | CYP1A2 | |
| SCHEMBL26701 | 0.80 | — | — | |
| SCHEMBL395642 | 0.80 | HSD17B10 (0.35) | — | |
| Vinylsulfonic Acid SCHEMBL27913512 | 0.79 | — | — | |
| Acrylonitrile SCHEMBL6536198 | 0.78 | ALDH1A1 (0.35) | ALDH1A1TSHRCYP1A2 | |
| Hydrochloric Acid SCHEMBL11756525 | 0.78 | — | — | |
| Ammonia Solution, Strong SCHEMBL1434426 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1995008310-A1 | IMPLANTABLE DEVICE FOR THE TREATMENT OF ×DEMAS | VOIR ET VIVRE E U R L (FR) | 1995-03-30 | — | — | WO | claimed |
| WO-2024129974-A1 | RECOMBINANT BACTERIA FOR USE IN THE TREATMENT OF DISORDERS IN WHICH OXALATE IS DETRIMENTAL | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4384611-A2 | RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH METHIONINE METABOLISM AND METHODS OF USE THEREOF | Synlogic Operating Company, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| US-20240191176-A1 | BACTERIA ENGINEERED TO SECRETE ACTIVE PROTEINS | SYNLOGIC OPERATING CO INC (US) | 2024-06-13 | — | — | US | disclosed |
| WO-2024113057-A1 | THERAPEUTIC BACTERIOPHAGE DISPLAYING CANCER CELL TARGETING MOIETIES ALONG WITH CYTOKINES FOR THE TREATMENT OF CANCER | TATUM BIOSCIENCE INC. (CA) | 2024-06-06 | — | — | WO | disclosed |
| US-20240180974-A1 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | SYNLOGIC OPERATING COMPANY, INC. | 2024-06-06 | — | — | US | disclosed |
| US-20240165168-A1 | ENGINEERED BACTERIA SECRETING THERAPEUTIC PROTEINS AND METHODS OF USE THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-05-23 | — | — | US | disclosed |
| WO-2024086557-A1 | RECOMBINANT BACTERIA EXPRESSING PHENYLALANINE AMMONIA LYASE, PHENYLALANINE TRANSPORTER AND L- AMINOACID DEAMINASE FOR REDUCING HYPERPHENYLALANINEMIA | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2024081768-A1 | BACTERIA ENGINEERED TO PRODUCE ACTIVE EPIDERMAL GROWTH FACTOR (EGF) AND THEIR MEDICAL USES | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240115666-A1 | COMPOSITIONS AND METHODS FOR REDUCING GAMMA-GLUTAMYLTRANSFERASE LEVELS | LILE METHOD RESEARCH, LLC (US) | 2024-04-11 | — | — | US | disclosed |
| EP-3003215-A2 | TRANSPLANTATION DEVICE AND METHOD OF USE | The Regents of the University of California (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160082236-A1 | TRANSPLANTATION DEVICE AND METHOD OF USE | UNIV CALIFORNIA (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160022592-A1 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS | THERABIOME, LLC | 2016-01-28 | — | — | US | disclosed |
| EP-2968187-A1 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS | THERABIOME, LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014197798-A2 | TRANSPLANTATION DEVICE AND METHOD OF USE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014152338-A1 | TARGETED GASTROINTESTINAL TRACT DELIVERY OF PROBIOTIC ORGANISMS AND/OR THERAPEUTIC AGENTS | KABADI MOHAN (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20040062809-A1 | Biocompatible polymer with a three-dimensional structure with communicating cells, a process for its preparation, and application in medicine and in surgery | UNIVERSITE PIERRE ET MARIE CURIE (PARIS VI) (FR) | 2004-04-01 | — | — | US | disclosed |
| US-6248321-B1 | PRECIPITATING USING AQUEOUS EMULSION | HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF NATURAL RESOURCES, CANADIAN FORESTRY SERVICE (CA) | 2001-06-19 | — | — | US | disclosed |
| US-4584103-A | REACTING WITH HYDROXYLAMINE, THEN DIFUNCTIONAL COMPOUND AND COMPOUND CONTAINING IONIZABLE GROUP | ALIGENA AG (CH) | 1986-04-22 | — | — | US | disclosed |
| US-4058509-A | INORGANIC HALIDE OR NITRATE | RHONE-POULENC S.A. (FR) | 1977-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115666-A1 | COMPOSITIONS AND METHODS FOR REDUCING GAMMA-GLUTAMYLTRANSFERASE LEVELS | GGT1, GGCT, TGM2 | ALDH1A1 2405/4885TSHR 1508/4885CYP1A2 3745/4885 |
| US-20240180974-A1 | MICROORGANISMS PROGRAMMED TO PRODUCE IMMUNE MODULATORS AND ANTI-CANCER THERAPEUTICS IN TUMOR CELLS | PDCD1, CD274, PDCD4 | ALDH1A1 2879/4885TSHR 4098/4885CYP1A2 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.